News | Contrast Media | September 12, 2018

International Group Publishes Research Roadmap on Gadolinium Retention

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore concerns about the safety of gadolinium-based contrast agents (GBCAs) and gadolinium retention. The workshop was co-sponsored by NIH, the Radiological Society of North America (RSNA) and the American College of Radiology (ACR). The organizers invited an international group of experts to discuss the current literature, identify knowledge gaps, prioritize future research initiatives and foster collaborative standardized studies. The group’s research roadmap was published today as a special report in the journal Radiology.

Attendees included researchers, GBCA manufacturers and representatives of the FDA, invited based upon their expertise in a diverse set of scientific and clinical disciplines relevant to the study of the chemistry, measurement, clinical manifestations or health-related effects of retained gadolinium in human tissues.

“It is our hope that this roadmap can serve to promote global, comprehensive collaborative research that effectively addresses the many important questions on the clinical significance of gadolinium retention in patients undergoing contrast-enhanced MRI examinations,” said Herbert Y. Kressel, M.D., co-author of the report, professor of radiology at Harvard Medical School in Boston and former editor of Radiology.

GBCAs have revolutionized magnetic resonance imaging (MRI), providing crucial, life-saving medical information often unavailable from other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide.

Although GBCAs are considered safe, some types of GBCAs have been associated with a rare condition called nephrogenic systemic fibrosis, which occurs mainly in patients with advanced kidney disease.

More recently, mounting evidence has demonstrated long-term retention of gadolinium in human tissues after GBCA exposure. However, there is currently no scientific evidence that the retained gadolinium causes harm. Moreover, there is no proven scientific association between a range of patient-reported symptoms and GBCA exposure.

“Despite the high level of interest in the gadolinium retention observed in the brains of patients receiving gadolinium-based contrast agents, in editing manuscripts on the topic submitted to Radiology, I noted the need for a more comprehensive, coordinated research program to more definitively address the many important, unanswered questions about gadolinium retention and its clinical significance,” Kressel said. “I was gratified by the support we received for the Gadolinium Retention-Research Roadmap workshop by NIH, RSNA and ACR.”

The greatest priorities in GBCA research are to determine if gadolinium retention adversely affects the function of human tissues, if vulnerable populations such as children are at greater risk, and if retention is causally associated with short-term or long-term clinical manifestations.

“The workshop was helpful in identifying the knowledge gaps that need to be addressed to understand the clinical significance of observed signal increases in the brains of patients receiving these agents, as well as those due to the retention of gadolinium in bone, skin and liver and other portions of the brain that do not demonstrate signal intensity increases on MRI,” Kressel said. “Understanding the biologic changes due to the retention in these areas is essential in determining the clinical significance, if any, of gadolinium retention.”

He added that the workshop was also helpful in pointing out the need to specifically study potentially vulnerable populations of patients who might be susceptible to release of gadolinium- based compounds from long-term reservoirs, in bone for example. Vulnerable patient populations include post-menopausal women, pregnant or lactating women, fetuses and young children with growing bones and ongoing organ development, and patients with chronic diseases who undergo a large number of contrast-enhanced MRI examinations.

The roadmap highlights knowledge gaps in GBCA research, proposes methods to address these gaps, identifies the feasibility and limitations of each approach and assesses priority levels. Crucial to these efforts is the standardization and validation of gadolinium and GBCA tissue measurement methods and quality assurance procedures. The authors also point out the need to study existing large population databases, such as the Mayo Clinic Study of Aging, with large numbers of patients who undergo contrast-enhanced MRI exams. According to Dr. Kressel, analysis of these types of databases may help identify specific areas of concern that could be addressed in prospective, controlled studies.

For more information: http://RSNA.org/radiology

Also see:

Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Iron Outperforms Gadolinium as MRI Contrast Agent

First FDA-Approved Study of Focused Ultrasound to Open Blood-Brain Barrier

VIDEO: Managing Gadolinium Safety

The Debate Over Gadolinium MRI Contrast Toxicity

Related Content

Brazil's Santa Casa Hospital System Chooses Carestream for Unified Diagnostic Workflow
News | PACS | May 22, 2019
Santa Casa de Misericordia has selected Carestream to replace its legacy diagnostic workflow technology across all...
Philips Lumify Earns U.S. Army Airworthiness Certification
News | Ultrasound Imaging | May 22, 2019
Philips announced that Philips Lumify, a point-of-care ultrasound device, has earned the U.S. Army Airworthiness...
Life Image and Bialogics Analytics Partner to Deliver Imaging Business Intelligence
News | Analytics Software | May 21, 2019
Life Image and business intelligence analytics provider Bialogics Analytics have formed a strategic partnership that...
Videos | Digital Radiography (DR) | May 20, 2019
This is a quick walk-around video showing the ...
Miami Cardiac and Vascular Institute Implements Philips Ingenia Ambition X 1.5T MRI
News | Magnetic Resonance Imaging (MRI) | May 17, 2019
Miami Cardiac & Vascular Institute announced the implementation of Philips’ Ingenia Ambition X 1.5T MR, the world’s...
Videos | Advanced Visualization | May 16, 2019
This is an example of how virtual reality is being used in neuro-radiology to better evaluate patients using advanced
Clarius Releases Clarius Live Ultrasound Telemedicine Solution
Technology | Ultrasound Imaging | May 15, 2019
Clarius Mobile Health released a telemedicine solution called Clarius Live. The simple-to-use feature allows any...
FDA Approves Zebra Medical Vision's HealthPNX AI Chest X-ray Triage Product
Technology | Artificial Intelligence | May 13, 2019
Zebra Medical Vision has received U.S. Food and Drug Administration (FDA) 510(k) clearance for HealthPNX, an artificial...
he DigitalDiagnost C90 is Philips newest premium digital radiography (DR) system, introduced here at the Radiological Society of North America (RSNA) 2018 meeting. It is the industry’s first radiography unit with a live camera image directly displayed at the tube head to provide a clear view of the anatomical area being scanned during the patient positioning process.
360 Photos | 360 View Photos | May 08, 2019
The DigitalDiagnost C90 is Philips newest premium ...
Chipmunk Health Chooses Philips HealthSuite for Telehealth Services
News | Teleradiology | May 06, 2019
Philips announced that telehealth service provider Chipmunk Health, with locations in the Netherlands and Canada, is...